RdRP-IN-10 

RdRP-IN-10 is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor with an IC₅₀ value of 5.78 μM. RdRP-IN-10 forms covalent binds with SARS-CoV-2 nsp8 Cys114, disrupts nsp8-nsp12 stabilizing interactions. RdRP-IN-10 inhibits SARS-CoV-2 RdRp-mediated RNA polymerization without interfering with RNA-RdRp complex binding. RdRP-IN-10 exerts antiviral effects in cellular models. RdRP-IN-10 can be used for the research of SARS-CoV-2 infection^[1].

RdRP-IN-10 (Compound 4) potently inhibits the SARS-CoV-2 nsp7/8/12 RdRp complex with an IC₅₀ of 5.78 μM^[1].
RdRP-IN-10 shows moderate antiviral activity in cellular models with an EC₅₀ of 87 μM^[1].
RdRP-IN-10 (20 μM) relies on covalent binding to Cys114 of nsp8 for inhibitory activity against the SARS-CoV-2 nsp7/nsp8/nsp12 RdRp complex, as activity is severely reduced against the nsp8^C114S mutant but preserved against the nsp8^C142S mutant^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

484.76

C₂₁H₂₀Cl₃N₃O₄

3099256-57-9

CC(CC(N1C2=CC=C(C=C2N=C1C3=CC(Cl)=CC(Cl)=C3O)NC(CCl)=O)C(O)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li L, et al. Fusion Strategy of DNA-Encoded Libraries Drives Discovery of Allosteric Inhibitors of SARS-CoV‑2 RdRp. JACS Au. 2026;6(2):1370-1381. Published 2026 Jan 23.  [Content Brief]